CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES · 2019-10-26 · CONSIDERATIONS...
10
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity NOVEMBER 18, 2016 4:00PM – 5:30PM New York Academy of Medicine NYC – Hosack Hall Co-provided by
Transcript of CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES · 2019-10-26 · CONSIDERATIONS...
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY
SKIN DISEASESImmune Regulation, Cutaneous Tolerance,
and T-cell Plasticity
NOVEMBER 18, 2016 4:00pm – 5:30pm
New York Academy of Medicine
NYC – Hosack Hall
Co-provided byCONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
1
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
INSTRUCTIONS FOR INTERACTIVE TECHNOLOGYIf you would like to use your tablet or mobile device to answer polling questions, view the onsite presentations, and submit questions to the faculty, please follow the instructions below:
1. Get Connected • PleaseconnecttotheCME Outfitters networkwithyourmobiledeviceor
laptop.Thisnetworkdoesnothaveapassword. * Please note that this network is a local network and does NOT mean you’re connected
to the internet.
• Onceyouhavejoinedthenetwork,gotoarraylearn.com
• Youarenowconnectedtothesymposium.Allcontentandpollingquestionscanbeviewedonyourdeviceaslongasyouareconnectedtotheabovelistednetwork.
2. Ask a Question to the Faculty • Pleaseclickon“Ask a Question”andtypeyourquestion.Pleaseincludethe
facultymember’snameifthequestionisspecificallyforthem.Yourquestionwillbesenttothefacultyforthequestionandanswerportionofthesession.
3. View and Take Notes on Presentation Slides • Pleaseclickonthe“Take a Slide Note”button.Ifyoudidnotenteryouremail
addresswhenyoujoinedthemeeting,youwillberequiredtodosofornotetaking.Whenthemeetingiscomplete,allyournoteswillbeemailedtoyouwithin5businessdays.
OBTAINING CREDITInordertoreceivecredit,pleasecompletetheevaluation/testformfoundonyourtableandturnthemintotheCMEOutfittersstaffonyourwayout.
PRESENTATION SLIDESDownloadableresourceswillbeavailableatwww.CMEOutfitters.com/SkinResources
2
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
This event is neither sponsored by nor endorsed by the Icahn School of Medicine.
NOVEMBER 18TH AGENDA
4:00pm – 4:10pm | Introduction:Tolerance,ImmuneRegulation,andDiseaseInterception
4:10pm – 4:40pm | Tregs,ImmuneRegulationintheSkin,andTolerance
4:40pm – 5:10pm | T-cellPlasticity:AFocusonTh-17T-cells
5:10pm – 5:30pm | Q&A
FACULTYJames G. Krueger, MD, PhD (moderator)D. Martin Carter Professor in Clinical InvestigationHead of Laboratory for Investigative DermatologyCo-director, Center for Clinical and Translational ScienceThe Rockefeller University HospitalNew York, NY
Vijay K. Kuchroo, DVM, PhDSamuel L. Wasserstrom Professor of NeurologyHarvard Medical SchoolDirector, Evergrande Center for Immunologic DiseasesHarvard Medical School and Brigham and Women’s HospitalBoston, MA
Michael D. Rosenblum, MD, PhDAssistant ProfessorDepartment of DermatologyUniversity of California San FranciscoSan Francisco, CA
#skinCME
For more information about this no fee symposium visit cmeoutfitters.com/skinCME
3
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
LEARNING OBJECTIVES• Recognize the role of cutaneous Tregs in tolerance induction and as a therapeutic target
in inflammatory skin diseases.• Describe how pathogenic T-cells may transdifferentiate into regulatory T-cells.• Illustrate how principles of disease interception apply to mechanisms of current and
emerging treatments in psoriasis.The following learning objectives pertain only to those requesting CNE credit:• Recognize the role of cutaneous Tregs in tolerance induction and as a therapeutic target
in inflammatory skin diseases.• Describe how pathogenic T-cells may transdifferentiate into regulatory T-cells.• Illustrate how principles of disease interception apply to mechanisms of current and
emerging treatments in psoriasis.
TARGET AUDIENCEDermatologists, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare providers with an interest in psoriasis and psoriatic arthritis.
COMMERCIAL SUPPORTER STATEMENTSupported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Novartis Pharmaceuticals Corporation.
ACCREDITATION STATEMENTSCME Credit:USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit:Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists:the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
CPE Credit: CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-16-032-L01-P Type: knowledge-based
4
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
James G. Krueger, MD, PhDTheRockefellerUniversityHospitalNewYork,NY
BiographyDr.KruegerisHeadoftheLaboratoryforInvestigativeDermatologyattheRockefellerUniversity.HealsoservesasaphysicianandCo-directoroftheCenterforClinicalandTranslationalScienceattheRockefellerUniversityHospital,andChiefExecutiveOfficeroftheRockefellerUniversityHospitalinNewYorkCity.
Dr.Kruegerearnedhisbachelor’sdegreefromPrincetonUniversityandaPhDinvirologyandcellbiologyfromtheRockefellerUniversity.HereceivedaMDfromCornellUniversityMedicalCollege,wherehealsocompletedaninternshipininternalmedicineandresidencyindermatology.Dr.KruegeriscertifiedbytheAmericanBoardofDermatology.
HisresearchgroupatRockefellerwasthefirsttoconductclinicaltrialswithspecific,targetedimmuneantagonistsinpsoriasisandthisworkestablishedthateliminationofpathogenicT-cellsfromskinlesionscouldreversethefullpathologicalphenotypeofpsoriasis.Sincethenhisgrouphasusedimmune-basedtherapeuticstodissectinflammatorypathwaysinpsoriasisandtoconductparallelpharmacogenomicstudiesthatdefinemechanismsoftargetedtherapeuticsinhumanpopulations.Amorerecentfocushasbeendefinitionofnewinflammatorypathways,aswellasnewtypesofinflammatorycellsinpsoriasislesionsthatarenowbeingtargetedwithnewbiologicdrugs.Hehasbeenanadvocateofbidirectionaltranslationalresearch(benchtobedsideandback)inhumansusingpsoriasisasamodelinflammatorydiseasetodissectpathogenicpathwaysthatcannotbestudiedinanimalmodels.
5
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
Vjay K. Kuchroo, DVM, PhDHarvardMedicalSchoolandBrighamandWomen’sHospitalBoston,MA
BiographyDr.VijayKuchrooistheSamuelL.WasserstromProfessorofNeurologyatHarvardMedicalSchool,SeniorScientistatBrighamandWomen’sHospital,andCo-DirectoroftheCenterforInfectionandImmunity,BrighamResearch
Institutes,Boston.VijayKuchrooisalsoanassociatememberoftheBroadInstituteandaparticipantinaKlarmanCellObservatoryprojectthatfocusesonTcelldifferentiation.HewasjustnamedtheDirectorofthenewlyformedEvergrandeCenterforImmunologicDiseasesatHarvardMedicalSchoolandBrighamandWomen’sHospital.Hismajorresearchinterestsincludeautoimmunediseases-particularlytheroleofco-stimulation-thegeneticbasisofexperimentalautoimmuneencephalomyelitisandmultiplesclerosis,andcellsurfacemoleculesandregulatoryfactorsthatregulateinductionofTcelltoleranceanddysfunction.Hislaboratoryhasmadeseveraltransgenicmicethatserveasanimalmodelsforhumanmultiplesclerosis.Dr.KuchroofirstdescribedtheinhibitoryreceptorTIM-3,whichisbeingexploitedasatargetforcancerimmunotherapy.HewasfirsttodescribethedevelopmentofhighlypathogenicTh17cells,whichhasbeenshowntoinducemultipledifferentautoimmunediseasesinhumans.Hehaspublishedover325originalresearchpapersinthefiledofimmunologyandapaperdescribingdevelopmentofTh17hasbeenoneofthehighestcitedpapersinimmunology.
Dr.KuchroocametotheUnitedStatesin1985andwasattheNationalInstitutesofHealth,BethesdaasFogartyInternationalFellowforayearbeforejoiningthedepartmentofpathologyatHarvardMedicalSchoolasaresearchfellow.HelaterjoinedtheCenterforNeurologicDiseasesatBrighamandWomen’sHospitalasafacultymemberin1992.
HeobtainedhisdegreeinveterinarymedicinefromtheCollegeofVeterinaryMedicine,Hisar,India.Subsequently,hespecializedinpathologyattheUniversityofQueensland,Brisbane(Australia)whereheobtainedaPhDin1985.HereceivedtheFredZ.EagerResearchPrizeandMedalforhisPhDresearchworkattheUniversityofQueensland.Basedonhiscontributions,hewasawardedtheJavitsNeuroscienceAwardbytheNationalInstitutesofHealthin2002andtheRanbaxyPrizeinMedicalResearchfromtheRanbaxyScienceFoundationin2011.HewasnamedDistinguishedEberlylecturerin2014andobtainedNobelLaureatePeterDohertyLectureandPrizein2014.
Dr.Kuchroohas25patentsandhasfounded6differentbiotechcompanies.HealsoservesonthescientificadvisoryboardsofanumberofbigpharmaceuticalcompaniesincludingPfizer,Novartis,Sanofi/GenzymeandGlaxo-Smith-Klein(GSK).
6
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
Michael D. Rosenblum, MD, PhDUniversityofCaliforniaSanFrancisco(UCSF)SanFrancisco,CA
BiographyDr.Rosenblum,scientifically,isaformallytrainedbasicimmunologist.Clinically,heisaboard-certifieddermatologist.HecompletedhisresidencyindermatologyatUCSFfollowedbyapost-doctoralresearchfellowshipatUCSF.HeiscurrentlyanAssistantProfessorintheUCSF
DepartmentofDermatology.Hededicates85%ofhistimetobasicresearchandtheremainingtimetakingcareofpatientswithspecificinflammatoryandautoimmuneskindiseases.Thecentralfocusofhislaboratoryistounderstandthefundamentalmechanismsofhowimmuneresponsesareregulatedinskin,andhowthisknowledgecanbeexploitedfortherapeuticbenefit.
7
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
DISCLOSURE DECLARATION ItisthepolicyofUSFHealthandCMEOutfitters,LLC,toensureindependence,balance,objectivity,andscientificrigorandintegrityinalloftheirCME/CEactivities.Facultymustdisclosetotheparticipantsanyrelationshipswithcommercialcompanieswhoseproductsordevicesmaybementionedinfacultypresentations,orwiththecommercialsupporterofthisCME/CEactivity.USFHealthandCMEOutfitters,LLC,haveevaluated,identified,andattemptedtoresolveanypotentialconflictsofinterestthrougharigorouscontentvalidationprocedure,useofevidence-baseddata/research,andamultidisciplinarypeerreviewprocess.Thefollowinginformationisforparticipantinformationonly.Itisnotassumedthattheserelationshipswillhaveanegativeimpactonthepresentations.
Dr.KruegerhasdisclosedthathehasreceivedresearchandgrantsupportfromAmgenInc.;BoehringerIngelheim;Bristol-MyersSquibbCompany;Dermira,Inc.;InnovadermResearchInc.;JanssenPharmaceuticals,Inc.;KadmonCorporation,LLC;KyowaHakkoKirinCo.,Ltd.;LEOPharmaInc.;Novartis;PAREXELInternationalCorporation;PfizerInc.;RegeneronPharmaceuticals,Inc.;andVitaePharmaceuticals,Inc.HeservesasaconsultantforAbbVieInc.;Baxter;BiogenIdec;BoehringerIngelheim;Bristol-MyersSquibbCompany;Dermira,Inc.;JanssenPharmaceuticals,Inc.;KadmanCorporation,LLC;Kineta,Inc.;EliLillyandCompany,Merck&Co..Inc.;Novartis;PfizerInc.;sanofi-aventisU.S.LLC;EMDSerono,Inc.;andXenoPort,Inc.
Dr.KuchroohasdisclosedthathehasreceivedresearchandgrantsupportfromNIH/NationalInstituteofNeurologicalDisordersandStroke(NINDS);NIH/NationalInstituteofDiabetesandDigestiveandKidneyDiseases(NIDDK);NIH/NationalInstituteofAllergyandInfectiousDiseases;Crohn’sandColitisFoundationofAmerica;GuthyJacksonCharitableFoundation;andSanofi/GenzymeCorporation.
Dr.RosenblumhasdisclosedthathehasreceivedgrantsupportfromAbbVieInc.andisastockshareholderofDelinia,Inc.
JeffreyHelfand,DO,MS(peerreviewer)hasnothingtodisclose.
KimberleyMurray,RN,MS(peerreviewer)hasnothingtodisclose.
DanielaV.DiBiase,MS(planningcommittee)hasnothingtodisclose.
SharonTordoff,CHCP(planningcommittee)hasnothingtodisclose.
DisclosureswereobtainedfromtheCMEOutfitters,LLCstaff:Nothingtodisclose.
DisclosureswereobtainedfromtheUSFHealthstaff:Nothingtodisclose.
CMEOutfitters,LLC,USFHealth,thefaculty,JansenBiotech,Inc.,andNovartisPharmaceuticalCorporationdonotendorsetheuseofanyproductoutsideoftheFDAlabeledindications.Medicalprofessionalsshouldnotutilizetheprocedures,products,ordiagnosistechniquesdiscussedduringthisactivitywithoutevaluationoftheirpatientforcontraindicationsordangersofuse.
8
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
NOTES
CONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY
SKIN DISEASESImmune Regulation, Cutaneous Tolerance,
and T-cell Plasticity
NOVEMBER 18, 2016 4:00pm – 5:30pm
New York Academy of Medicine
NYC – Hosack Hall
Co-provided byCONSIDERATIONS FOR FUTURE TREATMENT OF INFLAMMATORY SKIN DISEASES
Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
